Novartis spends $2.1B to snap up targeted radiotherapy drug for prostate cancer
Endocyte entered its targeted radioligand therapy, Lu-PSMA-617, into a Phase III study in June following Phase II data showing more than 60 percent response rate.
presented by
Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic
Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion. Under the terms of the deal, Merck, through a subsidiary, will get worldwide rights to develop and commercialize vintafolide for […]
FDA approval of imported Doxil puts Endocyte’s phase 3 trial back on track
Biopharmaceutical developer Endocyte (NASDAQ:ECYT) overcame a major hurdle in its path to drug approval and can now resume enrollment in its phase 3 clinical trial of an experimental drug for ovarian cancer. The company announced Monday that U.S. regulators approved the importation of cancer drug Doxil from Europe for the study. Endocyte’s phase 3 trial […]
Cancer drug developer Endocyte files for $86M IPO
West Lafayette, Indiana, biopharmaceutical company Endocyte Inc. hopes to raise more than $86 million from an initial public offering of stock. The company that develops small-molecule drug "conjugates" to treat cancer and inflammatory diseases would use offering proceeds to pay for clinical trials, repay debt and develop its drugs.
Cancer drug business Endocyte raises $26 million
The company is in the midst of a Phase 2 trial on an ovarian drug that works with women who have developed resistance to chemotherapy. Data from the study will be available as early as mid-2010.